2 weeks Ago By ABMN Staff
TransMedics Group, Inc. ( NASDAQ:TMDX – Get Free Report ) shares gapped up prior to trading on Friday . The stock had previously closed at $144.
56, but opened at $155.22. TransMedics Group shares last traded at $154.
70, with a volume of 398,322 shares trading hands. Analyst Ratings Changes Several brokerages have recently commented on TMDX. TD Cowen increased their price objective on TransMedics Group from $130.
00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.
00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Stephens increased their price objective on TransMedics Group from $151.
00 to $178.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th.
Finally, Robert W. Baird began coverage on shares of TransMedics Group in a research report on Tuesday, September 24th. They set an “outperform” rating and a $200.
00 target price for the company. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $174.
30. Check Out Our Latest Stock Analysis on TMDX TransMedics Group Stock Up 10.1 % TransMedics Group ( NASDAQ:TMDX – Get Free Report ) last posted its quarterly earnings results on Wednesday, July 31st.
The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.
14. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.
84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.
98%. The company’s revenue for the quarter was up 117.7% on a year-over-year basis.
During the same period last year, the firm posted ($0.03) earnings per share. As a group, equities analysts forecast that TransMedics Group, Inc.
will post 1.23 EPS for the current fiscal year. Insiders Place Their Bets In other news, insider Tamer I.
Khayal sold 2,958 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.
66. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,267,557.11.
The sale was disclosed in a filing with the SEC, which is available at this hyperlink . In other news, insider Anil P. Ranganath sold 4,289 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th.
The shares were sold at an average price of $152.20, for a total value of $652,785.80.
Following the transaction, the insider now directly owns 8,893 shares in the company, valued at approximately $1,353,514.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink .
Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.
77, for a total value of $463,725.66. Following the transaction, the insider now owns 20,843 shares in the company, valued at $3,267,557.
11. The disclosure for this sale can be found here . Over the last 90 days, insiders have sold 61,247 shares of company stock valued at $9,650,880.
Insiders own 7.00% of the company’s stock. Hedge Funds Weigh In On TransMedics Group Hedge funds and other institutional investors have recently bought and sold shares of the company.
Principal Financial Group Inc. grew its stake in shares of TransMedics Group by 21.3% in the fourth quarter.
Principal Financial Group Inc. now owns 21,929 shares of the company’s stock worth $1,731,000 after acquiring an additional 3,858 shares in the last quarter. Hsbc Holdings PLC raised its holdings in TransMedics Group by 19.
0% in the fourth quarter. Hsbc Holdings PLC now owns 41,650 shares of the company’s stock valued at $3,287,000 after acquiring an additional 6,650 shares in the last quarter. First Light Asset Management LLC lifted its stake in TransMedics Group by 22.
0% in the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after acquiring an additional 136,217 shares during the last quarter. Osterweis Capital Management Inc.
increased its position in shares of TransMedics Group by 78.5% in the 4th quarter. Osterweis Capital Management Inc.
now owns 64,565 shares of the company’s stock valued at $5,096,000 after purchasing an additional 28,390 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 10.
9% in the 4th quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock valued at $31,358,000 after purchasing an additional 38,951 shares in the last quarter.
99.67% of the stock is currently owned by hedge funds and other institutional investors. TransMedics Group Company Profile ( Get Free Report ) TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Read More Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter .
.
